robert lustig glp 1 Robert Lustig on Fatty Liver,

Individual GLP-1 telehealth programs are reviewed with attention to how providers typically operate in practice

In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide

This article breaks down the costs associated with GLP-1 drugs and what to consider

Learn what to expect in your first month, from appetite changes to weight loss milestones and potential side effects.

manufactured in cGMP-certified facilities, third-party tested for purity, and non-GMO, gluten-free, with zero artificial additives or fillers

June 6, 2025 A large retrospective review of more than 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of cardiovascular events, major limb events and inpatient admissions